BioArctic AB (BIOA_B) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much, and good morning, and welcome to BioArctic's presentation for the second quarter of twenty twenty six. Leukembi continues to progress really well with new approvals and launches. And BioArctic has signed additional strategic partnerships, and we will talk more about this in today's webcast. Next slide, please. BioArctic is listed at nastax.comlargecap, and this is our disclaimer. Next slide, please. I'm Gunilla Osvald, the CEO of BIOAARTIK, and I will share today's presentation with our CFO, Anders Martin Leung and our Chief R and D Officer, Johanna Felting and our Chief Commercial Officer, Anna Kayagranblad. Next slide, please. I will start our presentation by giving some key highlights. Next slide, please. BIOAARTIQ is among world leaders in two different areas. The first one is, regarding highly selective antibodies where we are innovative and we are generating highly selective antibodies targeting aggregated misfolded forms of toxic proteins. And here we have the front runner lecanumab and we also have projects targeting alpha synuclein and t d p 43, for example. The second area is when we're utilizing our brain transporter platform in an innovative and differentiated ways to deliver antibodies. And I also want to highlight that we are broadening the platform to enable more efficient transportation into the brain of other modalities and this could be utilized for enzymes and genetic medicines like ASOS and siRNA. So a lot of new innovation is coming from BIOATIQ. Next slide, please. We are already delivering on our 2,030 ambitions, and they are in four different areas. The first one is regarding Lykkembe to get it as an established treatment for Alzheimer's disease. And the Lekembi demand shows a steady growth to more and more patients on a glo...